These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 18562811)

  • 61. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Addressing statin adverse effects in the clinic: the 5 Ms.
    Katz DH; Intwala SS; Stone NJ
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):533-42. PubMed ID: 24770611
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Safety profile of statins].
    Prieto JC
    Rev Med Chil; 2001 Nov; 129(11):1237-40. PubMed ID: 11836874
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy.
    González CA; Rubio-Guerra AF; Pavía A; Redding FJ; Cervantes JL; Zacarías JL; Yza R; Carranza J; Fernández P; Morales E; Robles FJ; Leyva JL; Rodríguez L
    Clin Drug Investig; 2007; 27(5):333-7. PubMed ID: 17451281
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins.
    Danielak D; Karaźniewicz-Łada M; Główka F
    Drugs; 2018 Jul; 78(11):1105-1112. PubMed ID: 30003466
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Pharmacokinetics of statins].
    Fonseca FA
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():9-14. PubMed ID: 16400390
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
    Sparing R; Sellhaus B; Noth J; Block F
    Nervenarzt; 2003 Feb; 74(2):167-71. PubMed ID: 12596018
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Intensive cholesterol drug lowering: how to be sure about their safety].
    da Silva PM
    Rev Port Cardiol; 2010 Sep; 29(9):1405-18. PubMed ID: 21180182
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins.
    Kobayashi M; Chisaki I; Narumi K; Hidaka K; Kagawa T; Itagaki S; Hirano T; Iseki K
    Life Sci; 2008 Apr; 82(17-18):969-75. PubMed ID: 18402982
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
    Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
    Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials.
    Alsheikh-Ali AA; Karas RH
    Curr Atheroscler Rep; 2009 Mar; 11(2):100-4. PubMed ID: 19228482
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Muscle-related adverse effects of statins].
    Pohjola-Sintonen S; Julkunen H
    Duodecim; 2014; 130(16):1622-7. PubMed ID: 25269368
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination?
    Peluso I; Palmery M; Serafini M
    Curr Drug Metab; 2015; 16(9):833-46. PubMed ID: 26467069
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
    Generaux GT; Bonomo FM; Johnson M; Doan KM
    Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Statin-induced myopathy: the two faces of Janus.
    Arora R; Liebo M; Maldonado F
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):105-12. PubMed ID: 16891287
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?
    Cornier MA; Eckel RH
    Curr Atheroscler Rep; 2015; 17(2):475. PubMed ID: 25432858
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Simvastatin interactions with other drugs.
    Florentin M; Elisaf MS
    Expert Opin Drug Saf; 2012 May; 11(3):439-44. PubMed ID: 22416996
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [A new approach to the treatment of dyslipidemia].
    Kevelaitiene S; Slapikas R
    Medicina (Kaunas); 2008; 44(5):407-13. PubMed ID: 18541958
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mechanisms and assessment of statin-related muscular adverse effects.
    Moßhammer D; Schaeffeler E; Schwab M; Mörike K
    Br J Clin Pharmacol; 2014 Sep; 78(3):454-66. PubMed ID: 25069381
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.
    Golomb BA; Evans MA
    Am J Cardiovasc Drugs; 2008; 8(6):373-418. PubMed ID: 19159124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.